Latest news

Herzuma® (trastuzumab), a biosimilar for the treatment of breast cancer, now available in Europe

3 May 2018

FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY

Mundipharma celebrates two A’ Design Award & Competition wins for novel k-haler® inhaler device

25 Apr 2018

FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA

Mundipharma expands biosimilar portfolio with exclusive partnership deal across seven European countries for trastuzumab biosimilar, Herzuma

20 Mar 2018

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

Mundipharma opens its doors to local schools to inspire the next generation of scientists

14 Mar 2018

FOR LOCAL MEDIA ONLY

Mundipharma’s novel device, k-haler®, recognised for innovative packaging by iF DESIGN AWARDS

26 Feb 2018

FOR EUROPEAN MEDICAL AND PHARMA TRADE MEDIA

Mundipharma announces positive outcome of the European Decentralised Procedure (DCP) for Penthrox® (methoxyflurane) for emergency relief of moderate to severe pain

18 Dec 2017

FOR EUROPEAN PHARMA TRADE AND FINANCIAL MEDIA

Dr Alberto Martinez appointed President and CEO of Mundipharma International Ltd

13 Dec 2017

FOR BUSINESS AND PHARMA TRADE MEDIA

Mundipharma appoints Chief Information Officer

5 Dec 2017

FOR PHARMA AND IT TRADE MEDIA

Innovation is about more than science…

1 Dec 2017

by Christian Mazzi, Chief Commercial Officer, Mundipharma International

New data analysis published in the Journal of Allergy and Clinical Immunology: In Practice has identified five distinct patient clusters which may benefit from different consultation approaches

20 Nov 2017

For European medical and trade media

Picture of Will Dunlop author of article pharmaceutical market access in Europe

Putting BEACON into practice

news

2 Nov 2017

by Will Dunlop, Head of Market Access Mundipharma International

Mundipharma announces the positive outcome of the European Decentralised Procedure (DCP) for flutiform® k-haler®, a novel treatment for adolescents and adults with asthma

4 Oct 2017

For European trade and financial media only

CHMP positive opinion for opioid dependence treatment with Zubsolv®(buprenorphine and naloxone) in Europe

15 Sep 2017

For European medical media only

Mundipharma receives CHMP positive opinion for Nyxoid®(intranasal naloxone spray)

15 Sep 2017

For European medical media only

Largest ever flutiform®study confirms effectiveness and tolerability in real-world clinical practice: Findings from AffIRM study to be presented at ERS 2017

11 Sep 2017

For European medical and pharmaceutical media only

New data presented at ERS 2017 on flutiform® k-haler® (fluticasone propionate and formoterol), Mundipharma’s novel breath-triggered aerosol inhaler

10 Sep 2017

For European medical and trade media only

Mundipharma announces exclusive distribution agreement with Janssen for two primary care diabetes treatments Invokana®(canagliflozin) and Vokanamet®(canagliflozin /metformin) for selected European countries

4 Sep 2017

For European medical and pharmaceutical media only

1 2